Atossa Therapeutics to Present at the LD Micro 500 Virtual Conference on September 4, 2020
Atossa Therapeutics (Nasdaq: ATOS) announced that CEO Dr. Steven Quay will present at the LD Micro 500 virtual conference on September 4, 2020, at 9:00 AM ET. This presentation will be followed by a live Q&A session for registered investors and attendees. Additionally, Dr. Quay is available for one-on-one virtual meetings from September 1-4, 2020. Atossa focuses on developing innovative medicines for unmet medical needs, particularly in breast cancer and COVID-19. For further details, visit www.atossatherapeutics.com.
- None.
- None.
SEATTLE, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announces that Dr. Steven Quay, Atossa’s President and Chief Executive Officer, will give a virtual corporate presentation at the LD Micro 500 taking place online on Friday September 4, 2020 at 9:00 AM ET followed by a live Q&A session with registered investors and other conference attendees.
Webcast link: https://www.webcaster4.com/Webcast/Page/2019/36654
In addition, Dr. Quay will be available for virtual one-on-one meetings from September 1-4, 2020. To schedule a meeting please contact Eric Lahiji at eric@ldmicro.com.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Company Contact:
Atossa Therapeutics, Inc.
Kyle Guse CFO and General Counsel
Office: 866 893-4927
kyle.guse@atossainc.com
Investor Relations Contact:
Core IR
Office:(516) 222-2560
ir@atossainc.com
Source: Atossa Therapeutics, Inc.
FAQ
What is the date and time of Atossa Therapeutics' presentation at the LD Micro 500?
Who will represent Atossa Therapeutics at the LD Micro 500 conference?
How can investors schedule one-on-one meetings with Atossa Therapeutics during the LD Micro 500?
What is the main focus of Atossa Therapeutics?